Hemolytic Disease of the Fetus and Newborn in Latin America
Author Information
Author(s): Júnior Mário Dias Corrêa, Sosa Salvador Espino, Fernandes Milene, do Carmo Lais, de Oliveira Renato Watanabe, Kanevsky Gabriela
Hypothesis
What is the epidemiology and management of hemolytic disease of the fetus and newborn (HDFN) in Latin American countries?
Conclusion
The incidence, morbidity, and mortality of HDFN in Latin America are concerning, with RhD alloimmunization present in up to 70% of severe cases.
Supporting Evidence
- HDFN due to Rh alloimmunization ranged from 0.5 to 5 per 1000 live births.
- The perinatal mortality rate of HDFN is approximately 1.3–1.6 per 100,000 live births.
- Up to 47% of alloimmunized pregnancies were referred to reference centers only during the third trimester.
- About 60% of eligible pregnancies received anti-D IgG prophylaxis.
Takeaway
This study looks at a serious condition where a mother's blood can harm her baby, especially in Latin America, and finds that many cases could be prevented with better care.
Methodology
A scoping review was conducted by searching databases for articles on HDFN in Latin America, including observational studies and guidelines.
Potential Biases
The reliance on retrospective studies may introduce bias in the reported incidence and outcomes.
Limitations
The findings may not represent the full population due to the focus on reference centers and the retrospective nature of most studies.
Participant Demographics
Studies included pregnant individuals from Brazil, Chile, Mexico, Argentina, Colombia, Panamá, Paraguay, and Peru.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website